Genotypic inference of HIV-1 tropism using population-based sequencing of V3

Journal of Visualized Experiments

Volumn , Issue 46, 2010, Pages

  McGovern, Rachel A ^a   Richard Harrigan, P ^a   Swenson, Luke C ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

CCR5; Coreceptor; CXCR4; Genotyping; HIV; Immunology; Issue 46; Maraviroc; Sequencing; Tropism; V3

Indexed keywords

EID: 80055120891     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/2531     Document Type: Article

References (13)

1. Feng, Y., Broder, C.C., Kennedy, P.E., et al. HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane, G protein-coupled receptor. Science 272, 872-77 (1996).
2. Dragic, T., Litwin, V., Allaway, G.P., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673 (1996).
3. Dorr, P., Westby, M., Dobbs, S., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
4. Gulick, R.M., Lalezari, J., Goodrich, J. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359, 1429-1441 (2008).
5. Cooper, D.A., Heera, J., Goodrich, J. et al. Maraviroc versus efavirenz, both in combination with zidovudine/lamivudine, for the treatment of antiretroviral-naíve subjects with CCR5-tropic HIV-1. J. Infect. Dis. 201:803-813 (2010).
6. Low, A.J., McGovern, R.A., Harrigan, P.R. Trofile HIV co-receptor usage assay. Expert Opin. Med. Diagnostics 3: 181-191 (2000).
7. Sing, T., Low, A.J., Beerenwinkel, N., et al. Predicting HIV co-receptor usage based on genetic and clinical covariates. Antiviral Ther. 12: 1097-1106 (2007).
8. Harrigan, P.R., McGovern, R., Dong, W., et al. Screening for HIV tropism using population-based V3 genotypic analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1. Presented at: 5th International AIDS Society Conference. Cape Town, South Africa, 19-22 July 2009, Abstract WELBA101 (2009).
9. McGovern, R.A., Dong, W., Mo, T., et al. Optimization of clinically relevant cut-points for the determination of HIV co-receptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping. Presented at: 12th European AIDS Conference. Cologne, Germany, 11-14 November 2009, Abstract PE3.4/8 (2009).
10. Swenson, L.C., McGovern, R.A., Dong, W. et al. Optimization of clinically relevant cutoffs for determining HIV co-receptor use by population and "deep" sequencing methods. Presented at: 47th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA, USA, 29 October-1 November 2009, Abstract 297 (2009).
11. Swenson, L., McGovern, R., Dong, W., et al. Phenotypic screening for HIV tropism versus both population-based and "deep" sequencing. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2009 12-15 September (2009).
12. Swenson, L.C., Moores, A., Low, A.J., Thielen, A., Dong, W., Woods, C., Jensen, M.A., Wynhoven, B., Chan, D., Glascock, C., Harrigan, P.R. Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-based and 'Deep' Sequencing to Plasma RNA and Proviral DNA. Journal of Acquired Immune Deficiency Syndromes 54(5):506-510 (2010).
13. Swenson, L.C., Boehme, R., Thielen, A., McGovern, R.A., Harrigan, P.R. Genotypic determination of HIV-1 tropism in the clinical setting. HIV Therapy 4(3): 293-303 (2010).